Healthcare Industry News:   computer-aided detection 

Devices Radiology Oncology Distribution

 News Release - September 8, 2006

FUJIFILM Medical Systems USA Signs Agreement to Distribute iCAD Products for Growing Digital Mammography Market

iCAD Inc.'s SecondLook(R) Digital and TotalLook Solutions bring CAD and film digitizing capabilities to Fuji's digital mammography products

NASHUA, N.H. and STAMFORD, Conn., Sept. 8 (HSMN NewsFeed) -- iCAD®, Inc. (Nasdaq: ICAD ), an industry-leading provider of computer-aided detection (CAD) solutions, and FUJIFILM Medical Systems USA, the worldwide leader in digital mammography, announce that Fuji will offer iCAD products through their US sales channels. iCAD's SecondLook Digital and TotalLook products with the newly released version 7.2 broaden and strengthen the Fuji Computed Radiography for Mammography (FCRm) offerings by providing computer-aided cancer detection capabilities and a complete transition to digital mammography.

"The agreement with iCAD allows Fuji to offer a comprehensive solution to our customers. We plan to offer the standard-of-care iCAD products with our multiple digital mammography solutions," says Andy Vandergrift, National Marketing Manager, Women's Healthcare at Fuji. "FCRm represents the most recent digital mammography system to have passed the FDA's rigorous PMA process. Since the ACRIN-DMIST found digital mammography to be more accurate than film screen for a considerable percentage of women in the trial, more facilities have been actively seeking a digital mammography solution that best meets their clinical and workflow needs."

"iCAD is proud to be partnering with FUJIFILM Medical Systems, an industry leader in women's healthcare and the overall medical community," said Ken Ferry, President and CEO of iCAD. "Results of a recent survey on indicate strong market acceptance of FCRm digital mammography. We believe there are significant cancer detection and workflow benefits to combining digital mammography with computer-aided detection; and our newest version of SecondLook Digital for Fuji is specifically optimized for FCRm. iCAD's computer-aided detection has been shown to find cancers at an earlier, more treatable stage, helping to improve patient care and reduce costs. The SecondLook product specifically has been shown to find 72 percent of the cancers missed by radiologists on the previous exam."

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of computer-aided detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective and accessible for patients worldwide. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over eleven hundred women's healthcare centers worldwide. For more information, call +1 877 iCAD now or visit

About FUJIFILM Medical Systems USA, Inc.

As one of the Fuji Photo Film family of companies with 70 years of imaging experience and almost $25 billion in sales, FUJIFILM Medical Systems USA is a leading provider of diagnostic imaging products and network systems to meet the needs of healthcare facilities today and well into the future. Fuji's family of Imaging Systems products and technologies-including digital x-ray, women's healthcare imaging, dry imagers, and conventional x-ray film and equipment-are tailored to suit many different applications for a variety of imaging environments. The pioneer of Computed Radiography (CR), Fuji remains the market leader in digital x-ray with products that are clinically proven and constantly evolving to set the standard in digital imaging innovation. Fuji is headquartered in Stamford, CT.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

iCAD and SecondLook are registered trademarks of iCAD, Inc.

For iCAD investor relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at

For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via e-mail at

For Fuji public relations, contact Courtney Kraemer at 800.431.1850 x-3924 or via email at

Source: iCAD

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.